Are Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), McDermott International(NYSE:MDR) And Medgenics Inc(NYSEMKT:MDGN) Good Mid-day Trading Option?

Posted by admin November 24, 2014 0 Comment 715 views

New York, NY – GDP INSIDER  –  11/24/2014.

This article discusses three companies: Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), McDermott International(NYSE:MDR) and Medgenics Inc(NYSEMKT:MDGN)

Texas based pharmaceutical company, Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), traded as little as $0.90 to close to a new 52 week during Friday’s trading. The stock, which traded within a range of $0.90 to $0.96 during the day, had traded 20.5 million shares compared to 3 months average trading volume of 1.06 million, a figure that shows the investor’s spiking interest in the company. The company has recently partnered up with Ipsen, a French drug company, which will market telotristat outside of Japan and North America.

Are Lexicon Pharmaceuticals, Inc’s Shares Weak Enough To be Sold Soon? Read Our Free LXRX Analysis.

McDermott International(NYSE:MDR) fell five cents to close the day at $4.24,a 1.17% decrease in value during trading on Friday. The new closing price placed the stock 17.78% above its 52 week low of $3.60 and 54.70% further away from its 52 week high of $9.36. The stock’s rating is reiterated as BUY on November 6th, 2014 by the analysts at UBS. About 4.44 million shares traded hands during last session’s trading, a figure which is lower than its 30-day average trading volume of 6.43 million.

Can McDermott International Hit Its 52 Week High Mark In The Near Future? Click Here To Find Out More About MDR In Our Free Report.

Medgenics Inc(NYSEMKT:MDGN) saw its value decline by six cents as the stock fell 1.28% during Friday’s trading to close the trading session at $4.62. The ticker has a market capitalization of $88.50 million and traded within a range of $4.32 to $4.75 during the last trading session. Over the past 3 months, the stock has lost 26.43% in value and 10.65% in it 50-day simple moving average. On 12th November, the company entered into a research agreement with The Children’s Hospital Of Philadelphia (CHOP), according to which the Medgenics Inc is obliged to pay $4,475,765 for research purposes in its first year of the agreement.

Is This The Right Time To Invest In Medgenics, Inc? Receive Our Free MDGN Analysis.

About HotStockGains provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.

Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit for complete risks and disclosures.

Write Your Comment